Immatics Announces European Clinical Expansion of its Adoptive Cell Therapy Programs
- First patient has been treated in Germany in Immatics’ ACTengine® IMA202-101 trial
- German regulatory agency, Paul-Ehrlich-Institute (PEI), granted approval to commence another clinical ACTengine® trial in Germany investigating Immatics’ IMA203 product candidate
- Three clinical trial sites in Germany have started recruiting patients for Immatics’ ACTengine® IMA200 trial series
Immatics N.V., (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting cancer immunotherapies, announced today the treatment of the first patient in the IMA202-101 trial in Europe following the Clinical Trial Application (CTA, the equivalent of an IND approval by FDA) approval by Paul-Ehrlich-Institute (PEI), the regulatory body for cell and gene therapies in Germany. In addition, Immatics has been granted regulatory approval by PEI to initiate another phase I clinical trial in Germany to evaluate safety, tolerability and initial signs of clinical efficacy of IMA203.